This article, the search for which was motivated by your comment on China being stringent....this article refutes that belief:

https://www.statnews.com/2018/08/03/china-clinical-trials-infrastructure-transparency/

In fact here is what it says in part:

As an example, nearly all clinical research sites in China are hospitals, as there are no private practices. Because of that, clinical trial participants are treated exactly the same way as regular patients. That’s a problem because study staff — who are regular hospital employees — don’t have experience complying with Good Clinical Practice, putting the trial’s integrity, not to mention patient protection, at risk.

That makes me thing that Eagle's opinion has more than just conspiratorial value....perhaps HepaLink does have access to some data.  I wouldn't fall of my chair.